Browse News
Filter News
Found 485,526 articles
-
Generic drugs have been made at the plant for more than 40 years.
-
J&J Terminates Two Drugs From Pipeline
10/17/2017
J&J will not to pursue approval of sirukumab and discontinued the clinical trial for talacotuzumab. -
The deal combines HemoShear’s REVEAL-Tx platform with Takeda's drug discovery and development capabilities.
-
The combined company will be named Amneal Pharmaceuticals.
-
The money will be to provide patient and caregiver support, funding education and investing in the community.
-
3 Biotechs That Got Huge Boosts From Spark's FDA Panel Vote
10/17/2017
Spark develops a gene therapy treatment called Luxturna for a rare inherited blindness disease.
-
The cash will allow Gemini to advance multiple programs into the clinic.
-
Drug R&D Boom Lead Massachusetts Biotech Jobs to Hit an All-Time High
10/17/2017
And industry trade group MassBio has the jobs numbers and pipeline data to prove it.
-
Meet the Scientist Who's Obsessed With Discovering an Exercise Pill That Won't Give You Cancer
10/17/2017
Ronald Evans believes he’s much closer to a fat-burning, muscle-growing drug that won’t, uh, give you cancer.
-
MabVax Provides Corporate Overview, Business Outlook
10/17/2017
The company provided a corporate overview and business outlook for the remainder of 2017.
-
MiMedx Notified By FDA That It Can Proceed With Phase IIB Investigational New Drug Clinical Trial For Osteoarthritis Of The Knee
10/17/2017
MiMedx announced today that the Company has been notified by the FDA that its IND Phase 2B clinical study for osteoarthritis of the knee may proceed.
-
Chi-Med Reports Preliminary Phase II Data On Fruquintinib Combination In First-Line Lung Cancer
10/17/2017
Hutchison China MediTech Limited today reported preliminary clinical activity, safety, and tolerability data of fruquintinib.
-
Bristol-Myers Squibb Release: Opdivo Alone Or Combined With Yervoy In Exploratory Analysis From Phase I/II Study Checkmate -032
10/17/2017
Bristol-Myers Squibb Company today announced data evaluating Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) from the Phase 1/2 CheckMate -032 trial.
-
Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists
10/17/2017
Oramed announced today the publication of a new paper co-authored by Oramed's CSO, Dr. Miriam Kidron, Dr. Roy Eldor, Dr. Ehud Arbit and Dr. Yael Greenberg-Shushlav.
-
Nanology Announces First Patient Enrolled In A Phase II Clinical Trial Of Nanopac For Treatment Of Prostate Cancer
10/17/2017
NanOlogy LLC today announced the first patient has been enrolled in a clinical trial of NanoPac (nanoparticle paclitaxel) sterile suspension administered into the prostate for treatment of prostate cancer.
-
InMed Updates Pain Program
10/17/2017
InMed announced today additional pre-clinical results in the development of INM-405 for the treatment of pain.
-
ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer's Disease
10/17/2017
ProMIS Neurosciences today announced that its lead product candidate for Alzheimer's disease, PMN310, showed the desired binding profile of selectively targeting amyloid beta oligomers in a preclinical study directly comparing PMN310 to other amyloid beta-directed antibodies for Alzheimer's disease (AD).
-
TCS Launches 'Connected Clinical Trials' Platform on its Advanced Drug Development Suite
10/17/2017
Tata Consultancy Services, a leading global IT services, consulting and business solutions organization, has launched Connected Clinical Trials (CCT), an innovative Software as a Service (SaaS) platform that enables pharmaceutical companies to significantly transform patient engagement in clinical trials and improve the efficiency and accountability of the clinical supply process.
-
Trievr To Provide Major Pharmas With Request Management Platform To Meet New FDA Quality Metrics Requirements
10/17/2017
Trievr today announced that three of the top 10 major pharmaceutical companies have signed with Trievr to help facilitate and simplify the new FDA Quality Metrics (QM) Requirements.
-
Allergan Release: U.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05% Patents
10/17/2017
Allergan today acknowledged that the U.S. District Court for the Eastern District of Texas has issued an adverse trial decision finding that the four asserted patents covering RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05% are invalid.